Abstract
The use of calcineurin inhibitors was associated with reduced short- and long-term mortality in septic patients without an increased incidence of new-onset infections, hyperkalemia, severe hypertension, or acute kidney injury (AKI). However, CNI use may lead to adverse effects, such as liver injury and mild hypertension.
Introduction
Sepsis remains a critical medical emergency, characterized by a dysregulated immune response to infection. While the initial trigger is pathogenic, the subsequent organ failure and mortality are often driven by the host's own overactive inflammatory response, frequently described as a "cytokine storm." Finding a therapeutic "Goldilocks zone"—dampening this response without inducing profound immunosuppression—remains a major challenge in critical care. This study investigates the potential of repurposing calcineurin inhibitors (CNIs), such as cyclosporine A and tacrolimus, to modulate this response and improve outcomes in septic patients.
Methods
Researchers conducted a retrospective cohort study utilizing the Medical Information Mart for Intensive Care IV (MIMIC-IV) v2.2 database, which contains de-identified electronic health records for over 700,000 ICU admissions. To mitigate "confounding by indication," the authors employed Propensity Score Matching (PSM) at a 1:2 ratio. This matched 313 CNI users with 561 non-users based on baseline characteristics, including age, sex, comorbidities, and illness severity scores (SOFA and SAPS II).
Survival analysis was performed using Kaplan-Meier curves and Cox proportional hazard regression models to evaluate 28-day and 365-day mortality, alongside secondary outcomes such as duration of mechanical ventilation and vasopressor use.
Key Results
The study revealed a substantial survival benefit associated with CNI use. In the matched cohort, 28-day mortality was significantly lower in the CNI group (7.3%) compared to the control group (24.8%).
- Mortality Risk: After PSM, CNI use was associated with a Hazard Ratio (HR) of 0.26 (95% CI: 0.17–0.41) for 28-day mortality. This protective effect persisted at the one-year follow-up.
- Organ Support: Patients receiving CNIs were weaned from invasive mechanical ventilation faster, with 62% weaned within 24 hours compared to 52% in the control group (p=0.006).
- Safety Profile: Crucially, there was no significant increase in new-onset infections (24% vs 29%, p=0.135) or acute kidney injury. However, CNI use was linked to a higher incidence of liver injury (52% vs 31%) and mild hypertension (90% vs 76%).
Discussion and Limitations
The findings suggest that CNIs may prevent the "runaway" production of pro-inflammatory cytokines by inhibiting the nuclear translocation of NF-AT in T-cells. This modulation appears to protect against organ damage without leaving patients excessively vulnerable to secondary infections.
However, several limitations must be considered. As a retrospective, single-center study, these results indicate an association rather than direct causation. Sepsis is a heterogeneous syndrome, and further research is required to identify specific patient "endotypes" that benefit most. Additionally, the optimal dosing and timing for CNI administration remain undefined. While promising, these results necessitate validation through large-scale prospective randomized controlled trials before clinical implementation.
Summary updated